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A variety of natural products, which possess the 6H-dibenzo[b,d]pyran-6-one core have 
attracted our interest because of their unique biological activities. Among them, Hyalodendriol 
C was isolated from endophytic fungus associated with the hybrid ‘Neva of Populus deltoides’, 
P. nigra L along with hyalodendriol A and B. A variety of biological activities have been stated 
for hyalodendriol A-C, but only hyalodendriol C has shown significant antibacterial, larvicidal, 
and anti-fungal properties as mentioned previously in the literature. The interesting structural 
feature of this compound is the aromatic ring bearing chlorine atom on it. Natural products 
comprising a halogen on an olefinic, aromatic, heteroaromatic moieties as a substituent have 
gained considerable interest because of their multiple biological activities. Conversely, 
hyalodendriol A and B which do not possess chloro substituent, exhibited weaker activities 
than hyalodendriol C. Therefore, it was suspected that the presence of a chlorine atom was 
essential for the cytotoxicity of hyalodendriol C. In addition, urolithin is a metabolite of a class 
of compounds known as polyphenols which are found in various fruits, including 
pomegranates, nuts, and strawberries.  In recent years, research on urolithins has mainly 
focused on the first metabolite consisting of Uro-A and Uro-B, but we are interested in the 
second metabolite of urolithins that can reach systemic tissues. Uro-A glucuronide (Uro-A 
glur) and Uro-B glucuronide (Uro-B glur) have already been chemically synthesized by 
Villapharma Research S. L. (Parque Tecnológico de Fuente Alamo, Murcia, Spain). On the 
other hand, the chemical synthesis of Urolithin C 3-glucuronide (Uro-C 3-glur) has not been 
achieved, and the bioavailability of Uro-A glur and Uro-B glur is shown to be higher than that 
of Uro-C 3-glur. Therefore, we decided to synthesize Urolithin C 3-glucuronide, which needs 
to pursue beneficial health benefits. 
Urolithin is a biologically active compound that has anti-inflammatory, antioxidant, and 
anticancer properties. Urolithins, which are hydroxylated dibenzo[b,d]pyran-6-one derivatives, 
contain urolithin A (uro-A), urolithin B (uro-B), urolithin C (uro-C) and urolithin D (uro-D) 
derivatives which are produced  in vivo by the gastrointestinal microbiota of humans and 
different animals upon intaking ellagitannins (ETs), which are high molecular weight 
polyphenols and ellagic acids (EAs). There are many different phenolic antioxidants such as 
ETs and EAs in walnuts and pomegranates, which have been linked to potential preventive 
effects against chronic diseases like diabetes, cancer, cardiovascular diseases, and 
neurodegenerative diseases.  
3 
 
 A palladium-mediated intramolecular aryl-aryl coupling reaction was applied to the total 
synthesis of the bioactive natural products, Hyalodendriol C, and Urolithin C 3-Glucuronide. 
Keeping in view, the indispensable biological values of these compounds, we took the 
advantage of our established strategy to chemically synthesize hyalodendriol C and Urolithin 
C 3-Glucuronide. The total synthesis of hyalodendriol C got accomplished in 10 steps 
beginning with the preparation of phenol derivative from the commercially available 5-
methylbenzene-1,3-diol and synthesis of the corresponding benzoic acid derivative. On the 
other hand, the total synthesis of Urolithin C 3-Glucuronide has been accomplished in 11 steps 
starting from commercially available 3,4-dimethoxybenzaldehyde. Our group has reported several 
natural product syntheses using the Pd-mediated intramolecular biaryl coupling reaction with 
phenyl benzoate derivatives for forming the 6H-dibenzo[b,d]pyran-6-one ring system. 
Utilizing this transformation, we achieved the efficient total syntheses of hyalodendriol C and 
urolithin C 3-glucuronide. Molecular docking of the synthesized compounds was also 
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In the text following terms and reagents are abbreviated as follows 
Ac                                        acetyl 
Bn                                       benzyl 
Bu                                       butyl 
DBDMH                            1,3-dibromo-5,5-dimethylhydantoin 
DBU                                  1,8-diazabicyclo[5.4.0]undec-7-ene 
DIPEA                               diisopropylethylamine 
DMA                                 N, N-dimethylacetamide 
DMAP                               N, N-dimethyl-4-aminopyridine 
DMF                                  N, N-dimethylformamide 
EDC.HCl                        1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
Et                                       ethyl 
Me                                     methyl 
MOM                                 methoxymethyl 
NBS                                   N-bromosuccinimide 
NMR                                  nuclear magnetic resonance spectrometry 
PDC                                   pyridinium dichromate 
Ph                                      phenyl 
PPTS                                 pyridinium p-toluenesulfonate 
Pr                                       propyl 
TBAF                               tetrabutylammonium fluoride 
TBS                                  tert-butyldimethylsilyl 
TFA                                  trifluoroacetic acid 
THF                                  tetrahydrofran 
TLC                                  thin-layer chromatography 






1. General Introduction 
This thesis will describe new approaches to the total synthesis of natural dibenzo-α-pyrones 
and molecular docking studies of synthesized compounds. We used the Pd-catalyzed 
intramolecular biaryl coupling reaction of phenyl benzoate derivative to make the (6H-
dibenzo[b,d]pyran-6-one) ring system to synthesize such compounds.  
1.1 Dibenzo-α-Pyrones  
Dibenzo-pyrones (also known as dibenzo-pyranones, 6H-benzo[c]chromen-6-ones, and 6H-
dibenzo[b,d]pyran-6-ones) are heptaketide coumarin derivatives with a fused tricyclic nucleus. 
Fungi1, plants4, mycobionts2,3, and animal feces5,6 are the most common sources of Dibenzo-
α-Pyrones. These compounds are biosynthesized via  polyketide route in microorganisms or 
through the metabolism of natural ellagic acid and ellagitannins by intestinal bacteria. The 
group includes compounds with a variety of biological properties, including cytotoxicity, 
anticancer antioxidant,  anti-inflammatory, antiglycation, and antimicrobial activity. Dibenzo-
pyrones are also important intermediates in the development of cannabinoids7 and other 
pharmaceutically important compounds including androgen, progesterone, endothelial 
proliferation inhibitors, glucocorticoid receptor agonists, and antidyslipidemic agents.8,9 The 
pharmaceutical community is very interested in the possible applications of dibenzo-pyrones 
as antitumor agents, antiallergics, antioxidants, and antimicrobials. A few bioactive dibenzo-
pyrones have been chemically synthesized. 
 
 





1.2.1  Dibenzo-α-pyrones from Fungi 
Alternaria species and mycobionts are the primary sources of dibenzo-pyrones. Botrytis allii, 
Cephalosporium acremonium, Hyalodendriella sp. Ponipodef12, Microsphaeropsis olivacea, 
Penicillium verruculosum, and Phoma sp. are among the dibenzo-pyrone-producing fungi. 
Some biologically important Dibenzo-α-pyrones from Fungi are Neoaltenuene, Altertenuol, 
Alternariol 9-methyl ether, Graphislactone D, Alternariol, 4-Hydroxyalternariol 9-methyl 




Graphislactone A, R1 = CH3, R2 = H, R3 = OCH3, R4 = OH, R5 = OH, R6 = OCH3.      
Graphislactone B, R1 = CH3, R2 = H, R3 = OCH3, R4 = OH, R5 = OCH3, R6 = OCH3 
Graphislactone C, R1 = CH2OH, R2 = H, R3 = OCH3, R4 = OH, R5 = OH, R6 = OCH3 
Graphislactone E, R1 = OH, R2 = H, R3 = OCH3, R4 = OH, R5 = OH, R6 = OCH3 
Graphislactone F, R1 = OH, R2 = H, R3 = OCH3, R4 = OH, R5 = OH, R6 = OH 
Graphislactone G, R1 = CH3, R2 = Cl, R3 = OCH3, R4 = H, R5 = OH, R6 = OCH3 
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 Graphislactone H, R1 = CH3, R2 = H, R3 = OCH3, R4 = OCH3, R5 = OH, R6 = OCH3 
 Palmariol A, R1 = CH3, R2 = H, R3 = OH, R4 = Cl, R5 = OH, R6 = OCH3 
 Palmariol B, R1 = CH3, R2 = Cl, R3 = OH, R4 = H, R5 = OH, R6 = OCH3 
Figure 2. Structures of dibenzo-α-pyrones isolated from fungi. 
 
1.2.2. Dibenzo-α-pyrones from Plants 
Some dibenzo-α-pyrones from plants are listed as Autumnariniol, Autumnariol, 




Figure 3. Structures of the dibenzo-α-pyrones from plants 
 
1.2.3  Transformation of intestinal bacteria produces dibenzo-pyrones. 
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From animal manure, a group of dibenzo-pyrones known as urolithins with various phenolic 
hydroxylation patterns have been isolated. These dibenzo-pyrones can be present in 
pomegranates,  nuts, oak-aged wines, berries, muscadine grapes, medicinal plants, and tisanes, 
among other foods. They are not consumed in the intestine and are instead metabolized in vivo 




Urolithin A     R1=OH, R2=H, R3=OH, R4= H, R5=H 
Urolithin B     R1=OH, R2=H, R3=H, R4= H, R5=  H 
Urolithin C     R1=OH, R2=H, R3=OH, R4= OH, R5= H 
Urolithin D     R1= OH, R2=OH, R3=OH, R4=OH, R5=H 
Urolithin E      R1=OH, R2=OH, R3=OH, R4=H, R5=OH 
Urolithin M-5   R1=OH, R2= OH, R3= OH, R4=OH, R5=OH 
Urolithin M-6   R1= OH, R2=H, R3=OH, R4= OH, R5=OH 
Urolithin M-7   R1=OH, R2=H, R3= OH, R4= H, R5=OH 
Isourolithin A  R1= OH, R2= H, R3=H, R4=OH, R5= H 
Isourolithin B    R1=H, R2= H, R3=H, R4= OH, R5=H 
 
 







1.2.4   Biological Activities and Functions 
The chemical properties of dibenzo-pyrones and their derivatives have been explained widely. 
Some of them affect humans and animals as mycotoxins, while others affect plants as 
phytotoxins. They've been studied for their cytotoxic, antioxidant, antiallergic, antimicrobial, 
antinematodal, and acetylcholinesterase inhibitory properties. 
 
1.2.4.1  Toxicity on Human and Animals 
Mycotoxins produced by Alternaria fungi have long been associated with human and animal 
health. Toxins from Alternaria have been linked to a variety of negative effects on human and 
animal health (e.g., genotoxic, mutagenic, and carcinogenic).21 
 
1.2.4.2  Cytotoxic Activity 
Alternariol (10) was the most active metabolite in Alternaria dibenzo-pyrones, with cytotoxic 
activity on L5178Y mouse lymphoma cells22, as well as inhibitory activity on xanthine oxidase 
and protein kinase. Alternariol was discovered to be a topoisomerase I and II toxin, which can 
lead to DNA integrity deficiency in human colon carcinoma cells. It triggered cell death in 
human colon carcinoma cells by activating the mitochondrial apoptosis pathway. 23 
 
1.2.4.3 Antioxidant Activity 
Antioxidant activity was found in urolithin A, isourolithin A, and urolithin B  from Trapa 
natans fruits. Isourolithin A had the highest antioxidative effect, while urolithin B had a weak 
antioxidative effect. Since ellagic acid and ellagitannins are poorly processed in the intestine, 
urolithins tend to be responsible for ellagitannin-related biological activities. In a cell-based 








1.2.4.4 Antiallergic Activity 
Urolithin A, isourolithin A, and urolithin B,  isolated from the feces of Trogopterus xanthipes, 
were found to have hyaluronidase inhibitory activities with IC50 values of 1.33, 1.07, and 2.33 
mM, indicating antiallergic activity.24 
 
1.2.4.5 Other Bioactivities 
Antimicrobial, antinematodal, and antimalarial activities, as well as calmodulin-dependent, 
antiestrogenic and estrogenic, and acetylcholinesterase (AChE) inhibitory activities, are some 


















                                              Chapter 2 
2 Synthesis, and Characterization of Hyalodendriol C 
 
2.1 Introduction 
Hyalodendriol C25 as indicated in figure 1, chemically named as (2-chloro-7,9-dihydroxy-3-
methoxy-1-methyl-6H-dibenzo[b,d]pyran-6-one), a naturally occurring dibenzo-𝛼-pyrones26  
and possess a fused tricyclic nucleus.  In 2016, Zhou and co-workers reported the isolation and 
structural elucidation of hyalodendriol A-C from endophytic fungus associated with the hybrid 
‘Neva of Populus deltoides’, P. nigra L.25 A variety of biological activities have been stated 
for hyalodendriol A-C, but only hyalodendriol C has shown significant antibacterial, larvicidal, 
and anti-fungal properties as mentioned previously in the literature1). Particularly, it has shown 
strong antifungal effects with a value of IC50 of 11.6 µg mL
−1 in opposition to the spore 
germination of Magnaporthe oryzae. It has also exhibited strong larvicidal activities in the case 
of the yellow fever mosquito that is known to spread severe diseases for instance zika fever, 
dengue fever, chikungunya, and many other health problems. Conversely, hyalodendriol A and 
B which do not possess chloro substituent, exhibited weaker activities than those of 1. The 
inhibitory actions of all three analogues were tested against four phytopathogenic bacteria. 
Only Hyalodendriol C inhibited B. subtilis and X. vesicatoria with MIC values of 25 and 50    
μM, respectively, while compounds A and B did not inhibit the bacteria at the maximum 
measured concentration of 125 μM. Several natural products that possess (6H 
dibenzo[b,d]pyran-6-one) moiety are found to exhibit numerous biological activities.27 Among 
the varied biological activities of these compounds, the most exciting bioactivity is the 
prominent effect of some of the compounds with 6H-dibenzo[b,d]pyran-6-one core against 
SW1116 cancer cells.  
        The interesting structural feature of this compound is the aromatic ring bearing chlorine 
atom on it. Natural products comprising a halogen on an olefinic, aromatic, heteroaromatic 
moieties as a substituent have gained considerable interest because of their multiple biological 
activities. Chlorine is one of the most requisite halogens and it has been well studied in 
medicinal chemistry as an important constituent in drugs to cure diverse illnesses such as 
meningitis, cholera, typhoid plague, fungal infections, bacterial skin infections, respiratory and 
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neural complications.28 Therefore, it was suspected that the presence of a chlorine atom was 
essential for the cytotoxicity of hyalodendriol C. We have focused on the synthesis of 
hyalodendriol C by making use of Pd-catalyzed biaryl coupling reaction of phenyl benzoate 
derivative for making (6H-dibenzo[b,d]pyran-6-one) ring system. Since the palladium-
catalyzed coupling reaction for such compounds was successful as our group has already 
described, we took advantage and planned the total synthesis of hyalodendriol C. The Pd 
catalyzed biaryl coupling reaction is one of the most convenient techniques for the formation 
of carbon-carbon bonds between two aromatic rings among the various provisions of this kind 
of ring system. The intramolecular biaryl coupling reaction of phenyl benzoate derivatives 
using the Pd reagent has been documented to be widely useful for synthesizing several of these 
types of natural products. Our group has synthesized several natural products possessing 6H-
dibenzo[b,d]pyran-6-one ring system, by making use of palladium-catalyzed intramolecular 
biaryl coupling reaction with phenyl benzoate derivatives for forming the 6H-
dibenzo[b,d]pyran-6-one framework. 
       The sequential transformation of esterification between the corresponding benzoic acid 
and phenol, followed by the Pd-mediated coupling reaction, is shown in Scheme 1, as our 
simple synthetic strategy. 
 
                              
     hyalodendriol A                        hyalodendriol B                     hyalodendriol C           
 





Scheme 1. Synthetic outline of 6H-dibenzo[b,d]pyran-6-one ring system 
2.2 Synthesis of  phenol derivative 
The synthetic investigation of hyalodendriol C (1) started with the preparation of 4-chloro-5-
methylbenzene-1,3-diol by the known method, as an essential part of phenyl benzoate. 
Regioselective chlorination of commercially available orcinol to 2 using N-chlorosuccinimide 
(NCS) (scheme 2).29 
 
 
Scheme 2. Synthesis of phenol derivative 2 
 
2.3 Synthesis of benzoic acid derivative 
       On the other hand, through 5 step transformations, the corresponding benzoic acid was 
prepared as an important precursor for the esterification reaction.  First, 3,5-dimethoxyaniline 
was iodinated to 3, 5-Dimethoxyiodobenzene (3) with the substitution of the amino group into 
iodide via Sandmeyer reaction in presence of potassium iodide,30) which was eventually 
subjected to Vilsmeyer conditions for the introduction of formyl group to produce 6-Iodo-2, 4-
dimethoxybenzaldehyde (4).31 Then demethylation using BBr3 was carried out to obtain 2, 4-
Dihydroxy-6-iodobenzaldehyde (5).32 The dihydroxyl group of compound 5 must be 
tentatively protected by the benzyl group using benzyl bromide to yield 2, 4-Dibenzyloxy-6-
iodobenzaldehyde (6)32,33  before it was allowed for Pinnick oxidation to obtain the 
corresponding benzoic acid 7. Compounds 2 and 7 were prepared as per the methods already 
reported by our research group and results were found to be exactly matching including the 


















Esterification reaction  
Esterification between phenol derivative and corresponding benzoic acid derivative by using 
1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) and 4-
dimethylaminopyridine (DMAP) as a base was successful to yield the key precursor, 4-Chloro-
3-hydroxy-5-methylphenyl 2, 4-dibenzyloxy-6-iodobenzoate (8)34  in a moderate yield for the 
palladium mediated biaryl coupling reaction35 (scheme 4). Despite several attempts, the low 
yield continued to remain a concern, but almost 41% yield was observed via entry 6 when 2 
equivalent phenol was used and the reaction was performed at room temperature for 6 days. 
(Table 1). The low yield of the desired product was caused due to the condensation at both 
hydroxy groups. To find optimum reaction conditions, various variations were employed, such 
as a change in solvent, temperature, time, reagents, and equivalent weight of both substrates. 
Compound 9 was successfully achieved from compound 8 using MeI and K2CO3 as a base
36 
and this step was pleasingly found to offer a 74% yield.     
 
 
     




 Entry         Reagent           base              solvent        phenol eq       time      yield % of 8 a  
     1             EDC (3 eq)         DMAP           DCM           1.05            10 h            15 
     2             DCC (3 eq)         DMAP           DCM           1.05            24 h            20 
     3             DCC (3 eq)         DMAP           CHCl3          0.8             24 h             trace 
     4             DCC (3 eq)         DMAP           DMF             1.5             5 d              25 
     5             EDC (2 eq)         Et3N (5 eq)    DCM            1                5 d              trace 





2.4 Pd catalyzed intramolecular biaryl coupling reaction 
          The all-important intramolecular biaryl coupling reaction using Pd reagent was a 
significant potential for application to the construction of 2-Chloro-7,9-dibenzyloxy-3-
methoxy-1-methyl-6H-dibenzo[b,d]pyran-6-one (10). As shown in the table below the bi aryl 
intramolecular coupling reaction was observed in different conditions to achieve the maximum 
yield. We examined the intramolecular biaryl coupling reaction using Pd(OAc)2 and  NaOAc 
as base, in DMF at 150 °C with Triphenylphosphine (PPh3)   as ligand which produced 10 in 
56%  yield. In the second run Ag2CO3 was used as base with PPh3 but produced 10 in low yield 
as compare to the one with NaOAc being used as base. Combination of Pd(OAc)2   with NaOAc 
as base , with and without phosphine ligand produced the product in almost same percentage 
yield.   However, Pd(OAc)2 in presence of Ag2CO3 at high temperature (190 °C) lead to an 
improvement in the yield of 10. Finally, deprotection using 10% Pd/C in presence of H2
37
 
produced hyalodendriol C (1) successfully in a modest yield.  The spectral data of the synthetic 
compound is in line with the data provided in the literature. 
 
Table 2. Pd catalyzed cyclisation of 9 
 
 
Run          Catalyst         Ligand          Base           Time (h)      Temp.       Yield (%) of 10 a 
 
1                Pd(OAc)2        PPh3                   NaOAc           2                    130                     56% 
2 Pd(OAc)2        PPh3                   Ag2CO3  20                   reflux                29% 
3 Pd(OAc)2        None                  NaOAc          2                    130   57% 
4 Pd(PPh3)4        None                  NaOAc          5                    130                    32% 
5                 Pd(OAc)2        PPh3                  NaOAc           2                    reflux                11% 





In each case, the coupling reaction proceeded smoothly, producing the 
lactone compounds 10a and 10b in moderate to good yield. The product ratio 
of 10a and 10b changed dramatically with the reaction conditions. When 
Pd(OAc)2 with and without ligand was used, high regioselectivity was 
observed especially at high temperature (run 1 and 6), generating the product 
10a, which was reacted at the position ortho to the methyl group 
 
2.5 Significance of Palladium-Catalyzed coupling reaction 
One of the most effective methods for forming carbon-carbon bonds is through palladium-
catalyzed coupling reactions. Palladium's remarkable ability to form C-C bonds between 
properly functionalized substrates has allowed synthetic organic chemists to perform 
transformations that were previously impossible or only possible through multi-step processes. 
As a result, these coupling methodologies have changed the way people think about synthetic 
organic chemistry, and they're now widely used in organic synthesis and material science, as 
well as in the pharmaceutical, agrochemical, and fine chemical industries. In this context, the 
Nobel Prize in Chemistry awarded in 2010 to Richard F. Heck, Ei-ichi Negishi, and Akira 
Suzuki for their outstanding contributions to Pd-catalyzed cross-couplings in organic synthesis 
was well-deserved. In our opinion, the most important and elegant application of the coupling 
reactions is the synthesis of pharmaceuticals. 
   The generally accepted mechanism for Pd-catalyzed C-C coupling reactions is summarized 
below. First, Pd (II) is reduced to Pd (0) by a ligand or solvent, and Pd (0) is oxidatively added 
to the substrate. Next, at the reaction point on the phenoxy side, activation of the C-H bond 
occurs via the transition state of the intermolecular assisted intermolecular mechanism, and the 
C-Pd bond is formed by the base abstracting the proton. Finally, reductive elimination forms a 
biaryl bond, constructing a 6H-dibenzo [b,d] pyran-6-one backbone and regenerating Pd (0). 





































2.6  Experimental Section 
General: All reactions were executed under N2 atmosphere. Reaction solvents were used after 
purification by the standard methods. Reaction progress was observed with the help of thin-
layer chromatography by making use of silica gel (70 F254) TLC plates and UV light as an agent 
for visualizing. Silica gel (particle size: 100−200 and 230−400 mesh). Melting points (mp) 
were obtained using the Yanaco micro melting point apparatus and are uncorrected. With the 
Shimadzu FTIR 8400 spectrophotometer, the IR spectra were acquired. The JOEL α-400 MHz 
instrument was utilized for obtaining 1H and 13C NMR spectra with the couplings being shown 
in Hertz and chemical shift being expressed as 𝛿 ppm. Silica gel column chromatography was 







A 500-mL, single-necked, round-bottomed flask, equipped with a 3-cm, egg-shaped, magnetic 
stir bar was charged with a solution of 5-methylbenzene-1,3-diol, (5 g, 50.3 mmol) in CHCl3 
(200 mL). The reaction mixture was cooled to 0 °C by using an ice bath. To the resulting 
solution, was added N-Chlorosuccinimide (NCS) (6.4 g, 48.35 mmol) with stirring over a 
period of 5 min before bringing it back to room temperature. A TLC analysis using ethyl 
acetate:hexane (1:5) indicated the reaction was complete. The solution was decanted into water 
(120 mL) after being stirred at room temperature for 8 h and stirred for 5 more min. The mixture 
was transferred to a 500 mL separatory funnel. The organic layer was separated, and the 
remaining aqueous layer was extracted with CH2Cl2 (3 × 100 mL). The combined organic 
extracts were washed with saturated brine (100 mL), dried over anhydrous MgSO4, and 
concentrated using a rotary evaporator to yield a white solid which was collected and dried 







3, 5-Dimethoxyiodobenzene (3) 
A 300-mL, single-necked, round-bottomed flask, equipped with a 3-cm, egg-shaped, magnetic 
stir bar was charged with an ice-cooled solution of 3,5-dimethoxyaniline 5 g (32.6 mmol) in 
55 mL water, H2SO4 (5 mL) was added drop wise to the solution. After the solution had cooled 
down to -10 to -15 °C, a solution of NaNO2 (2.635 g, 38.2 mmol) in 10 mL water was added 
accompanied by the addition of Et2O 25 mL. To limit the evolution of N2, a solution of 
potassium iodide (KI) (16.42 g, 98.9 mmol) in water (15 mL) was added gently and kept at 
stirring at room temperature. A TLC analysis using ethyl acetate:hexane (1:2) indicated the 
reaction was complete. The mixture was transferred to a 500 mL separatory funnel. The organic 
layer was separated, and the remaining aqueous layer was extracted with diethyl ether (3 × 100 
mL). The combined organic layer was washed with Na2S2O3.5H2O (aq) (3×30 mL), 1M HCl 
(50 mL), 2M NaOH (50 mL). The combined organic extracts were washed with saturated brine 
(100 mL), dried over anhydrous MgSO4, and concentrated using a rotary evaporator to yield a 
white solid which was collected and dried under vacuum. Two times recrystallization from 
















6-Iodo-2, 4-dimethoxybenzaldehyde (4) 
To a 200-mL, three-necked, round-bottomed flask, equipped with a 4.0-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with a solution 
of 3, 5-Dimethoxyiodobenzene (3) (4.42 g, 17.04 mmol) in DMF (16 mL), and stirring was 
begun to dissolve the solid. POCl3 (5.5 mL, 59.64 mmol) was added dropwise via the addition 
funnel with stirring over a period of 20 min. The reaction flask was then placed in a pre-heated 
oil bath at  75 °C for 4 hours. During this time change in colour from yellowish to brownish 
was observed. A TLC analysis of the solution using Ethyl Acetate: hexane (3:2) indicated the 
reaction was complete. After cooling for 10 min, the reaction mixture was poured into a 300-
mL Erlenmeyer flask containing crushed ice (50 g). The resulting mixture was cooled in an ice 
bath with continuous stirring for 10 min.    The mixture was transferred to a 500 mL separatory 
funnel using ethyl acetate (100 mL). The organic layer was separated, and the remaining 
aqueous layer was extracted with ethyl acetate (4 × 150 mL). The combined organic extracts 
were washed with saturated aqueous NaHCO3 (50 mL), dried over anhydrous MgSO4, and 
concentrated using a rotary evaporator to yield a yellow solid. Purification of this material by 
















2, 4-Dihydroxy-6-iodobenzaldehyde (5) 
To a 200-mL, three-necked, round-bottomed flask, equipped with a 2.5-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with BBr3 (38.8 
mL, 38.808 mmol), a solution of 6-Iodo-2, 4-dimethoxybenzaldehyde (4) (2.70 g, 9.24 mmol) 
in dry CH2Cl2 (50 mL) was slowly added to the mixture via the addition funnel with stirring 
continued for 20 h. [Caution: BBr3 was handled very carefully]. During the addition process, 
the color of the reaction mixture changed from yellow to red.  A TLC analysis of the solution 
using ethyl acetate:hexanes (1:3) indicated the reaction was complete. Later, iced water (60 
mL), was added very slowly with continued stirring, a precipitate began to form during the 
addition of water. The reaction mixture was acidified with 1 M aq HCl (28 mL). The precipitate 
was filtered to obtain a pure brown solid product. Whereas the filtrate was transferred to a 500-
mL separatory funnel and the aqueous layer was extracted with EtOAc (3×50 mL). The 
combined organic extracts were washed with saturated aqueous brine (60 mL), dried over 
anhydrous MgSO4, and concentrated using a rotary evaporator to yield a brown oil. Purification 
of this material was achieved by column chromatography (15-cm × 2-cm column), eluted with 













2, 4-Dibenzyloxy-6-iodobenzaldehyde (6) 
To a 200-mL, three-necked, round-bottomed flask, equipped with a 3.0-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with a solution 
of 2, 4-Dihydroxy-6-iodobenzaldehyde (5) (1.65 g, 7.83 mmol) in acetone (34 mL)  and stirring 
was begun to dissolve the solid. K2CO3 (2.165 g, 15.66 mmol) was then added and stirring was 
continued for 10 min. Benzyl bromide (2.21 ml, 18.79 mmol) was slowly added to the 
mixture via the addition funnel with stirring continued at room temperature. During the 
addition process, the color of the reaction mixture changed from brown to yellow. After 13 h a 
TLC analysis of the solution using ethyl acetate:hexanes (1:3) indicated the reaction was 
complete. The reaction mixture was quenched by the slow addition of water (30 mL) and 
diluted with EtOAc (100 mL).  Then the reaction mixture was filtered and the solid part was 
discarded. The mixture was transferred to a 500-mL separatory funnel and proceeded with 
extractive workup with EtOAc (3×50 mL), the organic layer was washed with saturated brine 
(50 mL), dried over anhydrous MgSO4, and concentrated to get oil like crude. The residue was 


















2, 4-Dibenzyloxy-6-iodobenzoic acid (7) 
A 300-mL, single-necked, round-bottomed flask, equipped with a 2.5-cm, egg-shaped, 
magnetic stir bar was charged with a solution of 2, 4-dibenzyloxy-6-iodobenzaldehyde 6 (930 
mg, 2.09 mmol) in t-BuOH (27 mL), and stirring was begun to dissolve the solid. MeCN (7.75 
mL), NaH2PO4.2H2O (2.6 g, 16.74 mmol) and 2-methyl-2-butene (5.09 mL, 48.14 mmol) were 
added. The solution was cooled to 0 ˚C and NaClO2 (1.5 g, 16.74 mmol) dissolved in water (12 
mL) was dropwise added and kept on stirring at room temperature. A TLC analysis of the 
solution using ethyl acetate: hexane (1:3) indicated the reaction was complete After stirring for 
2 h, EtOAc (100 mL) water (20 mL) was added and stirred for 5 more min. The mixture was 
transferred to a 500-mL separatory funnel and the organic layer was separated. The aqueous 
phase was extracted with  EtOAc (3×50 mL), and the combined organic layer was washed with 
saturated brine (50 mL), dried over anhydrous MgSO4, and concentrated under reduced 













4-Chloro-3-hydroxy-5-methylphenyl 2, 4-dibenzyloxy-6-iodobenzoate (8) 
To a 100-mL, three-necked, round-bottomed flask, equipped with a 1.0-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with a solution 
of  2, 4-Dibenzyloxy-6-iodobenzoic acid (7) (500 mg, 1.087 mmol) in DCM (16 ml) and 
stirring was begun to dissolve the solid. N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC.HCl) (245 mg, 1.08 mmol), 4-Dimethylaminopyridine (DMAP) (65 mg, 
0.54 mmol) and 4-Chloro-1,3-dihydroxy-5-methylbenzene (substrate 2) (345 mg, 1.17 mmol) 
were added. The reaction mixture was stirred for 6 days at room temperature. A TLC analysis 
of the solution using (hexane/EtOAc/ CH2Cl2, 3/1/0.25) indicated the reaction was 
complete.  The reaction mixture was then poured into water and then aqueous layer was 
extracted with CH2CL2 (3×30 mL). The organic layer was washed with saturated brine (50 
mL), dried over anhydrous MgSO4, and concentrated under reduced pressure to give a residue 
that was subjected to column chromatography (silica gel) (hexane/EtOAc/ CH2Cl2, 3/1/0.25). 
White solid product was obtained (269 mg, 41%) yield, mp 162.9-164.2 °C; IR KBr/cm : 3384, 
1732, 1589, 910, 762, 611; 1H-NMR (400 MHz, CDCl3) δ 7.41-7.35 (m, 10H), 7.08 (d, J = 7.3 
Hz, 1H), 6.72 (d, J = 2.7 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H), 6.58 (d, J = 2.7 Hz, 1H), 5.66 (s, 1H), 5.08 
(s, 2H), 5.04 (s, 2H), 2.31 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 165.9, 161.1, 157.3, 152.0, 149.6, 
137.6, 135.9, 135.8, 128.8, 128.8, 128.5, 128.4, 127.7, 127.6, 122.9, 118.0, 116.8, 115.9, 107.5, 101.0, 









4-Chloro-3-methoxy-5-methylphenyl 2, 4-dibenzyloxy-6-iodobenzoate (9) 
To a 100-mL, three-necked, round-bottomed flask, equipped with a 1.0-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with a solution 
of to a solution of 4-Chloro-3-hydroxy-5-methylphenyl 2, 4-dibenzyloxy-6-iodobenzoate (8) 
(240 mg, 0.39 mmol) in DMF (2.4 mL) and stirring was begun to dissolve the solid. K2CO3 
(82 mg, 0.60 mmol) and methyl iodide (0.025 mL) were added to the reaction mixture. A TLC 
analysis of the solution using EtOAC:hexanes (1:3) indicated the reaction was complete After 
24 hours of stirring at room temperature, the reaction mixture was poured into the water 
accompanied by layer separation. The aqueous layer was extracted with EtOAC (3×30 mL) 
whereas, the washing of the combined organic layer was done with additional water (3×20 mL) 
and one time with sodium chloride solution, dried over anhydrous MgSO4, and evaporated to 
give a residue. Two times recrystallization from EtOAc yielded white coloured solid product 
(180 mg, 74%), mp 94.4-95.5 °C ; IR KBr/cm :1745, 1696, 831, 736; 1H-NMR (400 MHz, 
CDCl3) δ 7.43-7.35 (m, 10H), 7.09 (d, J = 1.8 Hz, 1H), 6.65 (d, J = 5.5 Hz, 2H), 6.53 (s, 1H), 
5.06 (d, J = 2.3 Hz, 4H), 3.72 (s, 3H), 2.33 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 166.0, 
161.1, 157.3, 155.6, 149.3, 138.4, 135.8, 128.9, 128.7, 128.5, 128.4, 127.8, 127.7, 122.9, 120.1, 
116.8, 115.8, 103.7, 101.0, 92.8, 77.4, 77.1, 76.8, 71.0, 70.7, 56.3, 20.5; HRMS (EI) m/z [M+] 









To a 100-mL, three-necked, round-bottomed flask, equipped with a 1.0-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (nitrogen inlet) was charged with  a solution 
of 4-Chloro-3-methoxy-5-methylphenyl 2, 4-dibenzyloxy-6-iodobenzoate (9) (154 mg, 0.24 
mmol) in DMA (3 mL), Pd(OAc)2 (5.60 mg, 0.46 mmol) and Ag2CO3 (138.09 mg, 0.50 mmol) 
were added. The reaction mixture was then stirred for 5 min at rt and subsequently heated at 
190 °C for 2 h. Later, at room temperature, the reaction mixture was cooled down, diluted with 
EtOAc, filtered to remove undissolved materials and then the filtrate was poured into 10 ml 
water and extracted with EtOAc (3×20 mL). The organic layer was washed with water and 
sodium chloride solution, dried over anhydrous MgSO4 and evaporated to give a brown mixture. 
Column chromatography (silica gel) (hexane/EtOAc, 3/1) was employed to yield 10 as white 
powder (74 mg, 60%), mp 187.1-188.3 °C; IR KBr/cm : 1720, 1600, 823, 734; 1H-NMR (400 
MHz, CDCl3) δ 7.59 (d, J = 6.9 Hz, 2H), 7.44-7.36 (m, 8H),7.14 (d, J = 1.8 Hz, 1H), 6.76 (s, 
1H), 6.67 (d, J = 1.8 Hz, 1H), 5.29 (s, 2H), 5.17 (s, 2H), 3.94 (s, 3H), 2.70 (s, 3H); 13C-NMR 
(100 MHz, CDCl3) δ 163.5, 162.6, 157.3, 156.1, 151.7, 139.7, 136.3, 135.8, 134.9, 128.9, 128.7, 
128.5, 127.9, 127.4, 126.8, 120.6, 112.4, 104.8, 104.6, 100.4, 98.4, 77.4, 77.1, 76.8, 71.0, 70.5, 














To a 25-mL, two-necked, round-bottomed flask, equipped with a 0.5-cm, egg-shaped stir bar 
and fitted with an addition funnel and a condenser (hydrogen inlet) was charged with a solution 
of 2-Chloro-7,9-dibenzyloxy-3-methoxy-1-methyl-6H-dibenzo[b,d]pyran-6-one (10) (42 mg, 
0.086 mmol) in 1:1 MeOH/EtOAc (1 mL) followed by the addition of 10% Pd/C (52 mg). The 
resulting mixture was stirred for 6 h at rt under H2 atmosphere. A TLC analysis of the solution 
using EtOAC:hexanes (1:2) indicated the reaction was complete  after which the mixture was 
filtrated to remove the catalyst and eluted with EtOAc. The volatiles were evaporated to 
provide the crude which was subjected to column chromatography (hexane/EtOAc, 2:1) to 
yield hyalodendriol C (1) as brown solid, (10 mg, 35%), mp 235 °C-237 °C. IR KBr/cm :3284, 
2362, 1652, 1070, 983; 1H-NMR (400 MHz, DMSO-D6) δ 7.21 (d, J = 1.8 Hz, 1H), 7.16 (s, 
1H), 6.42 (d, J = 1.8 Hz, 1H), 3.94 (s, 3H), 2.81 (s, 3H); 13C-NMR (100 MHz, DMSO-D6) δ 
163.9, 150, 132.2, 129.2, 67.9, 40.6, 40.4, 40.2, 40.0, 39.8, 39.6, 39.4, 38.6, 30.3, 29.5, 28.9, 
















3 Synthesis and characterization of urolithin C 3-glucuronide 
  
3.1 Introduction 
Over recent years, it has been reported that gastrointestinal microbiota metabolize xenobiotics, 
which are produced from natural products57 Urolithins, which are hydroxylated 
dibenzo[b,d]pyran-6-one derivatives, contain urolithin A (uro-A), urolithin B (uro-B), urolithin 
C (uro-C) and urolithin D (uro-D) derivatives which are produced in vivo by the gastrointestinal 
microbiota of humans and different animals upon intaking ellagitannins (ETs), which are high 
molecular weight polyphenols and ellagic acids (EAs).58-63 There are many different phenolic 
antioxidants such as ETs and EAs in walnuts and pomegranates, which have been linked to 
potential preventive effects against chronic diseases like diabetes, cancer, cardiovascular 
diseases, and neurodegenerative diseases.64-65 The bioavailability of ETs and EAs is much 
lower than transformed urolithins. Glucuronides of uro-A, uro-B, uro-C, and sulfate conjugates 
are formed by urolithins which circulate in the plasma. Total concentrations of these 
metabolites can reach a range of 0.2-20 μM .62 Although it is suggested that positive health 
effects are arising from the metabolism of ETs, there is not enough in vivo research. So, a clear 
evaluation in terms of the in vivo biological effects of these metabolites is necessary.64 In 
addition to these reports, it is shown that phase-Ⅱ metabolites of urolithins, which are primarily 
glucuronide and sulfate conjugates, can reach systemic human tissues66. In recent years, 
research regarding urolithins has concentrated on phase-Ⅰ metabolites which are composed of 
mainly uro-A and uro-B, whereas we have been interested in phase-Ⅱ metabolites of urolithins. 
Uro-A glucuronide (uro-A glur) and uro-B glucuronide (uro-B glur) were already chemically 
synthetized and purified by Villapharma Research S. L. (Parque Tecnológico de Fuente Alamo, 
Murcia, Spain)68-69. On the other hand, the chemical synthesis of Uro-C 3-glur has not been 
completed and the bioavailability of uro-A glur and uro-B glur has been shown to be much 
more than uro-C 3-glur70. Thus, we have decided to synthesize Urolithin C 3-Glucuronide 
which is needed to pursue the advantageous health effects. Our retrosynthetic analysis to form 
Uro-C 3-glur is outlined in Scheme 1. Firstly, we aimed at forming the 6H- dibenzo[b,d]pyran-
6-one skeleton of urolithin as an intermediate with a palladium catalyst so that the final product 




the coupling compound could be derived from the commercially available starting materials 
3,4-dimethoxybenzaldehyde and resorcinol.  
 
 





















































































































Figure 2. They undergo phase II glucuronidation or sulfate conjugation to produce the second 
metabolites, Urolithin A Glucuronide, Urolithin B Glucuronide, Urolithin A Sulfate, and 




































Urolithin B Sulfate  
 






















Scheme 2.  Mechanism of the intramolecular biaryl coupling reaction. 
  
First, Pd (II) is reduced to Pd (0) by a ligand or solvent, and Pd (0) is oxidatively added to the 
substrate. Next, at the reaction point on the phenoxy side, activation of the C-H bond occurs 
via the transition state of the intermolecular assisted intermolecular mechanism, and the C-Pd 
bond is formed by the base abstracting the proton. Finally, reductive elimination forms a biaryl 
bond, constructing a 6H-dibenzo [b, d] pyran-6-one backbone and regenerating Pd (0). 
However, this intramolecular biaryl coupling reaction has a problem of regioselectivity than 
the estimation mechanism shown in Scheme 4. That is, if a substituent is present at the 3-







In order to investigate the regioselectivity in this reaction, experiments were conducted using 














In Entry 1 and 2, K2CO3 is used as the base, and the conditions with and without the ligand are 
examined. The production ratios of 2a and 3a were slightly different with and without the ligand. 
In Entry 3 and 4, the base was changed to Ag2CO3 for examination. The 2a production ratio 
was highest in the absence of the ligand, entry 3. The 2a and 3a production ratios were reversed 
in the presence of the ligand, entry 4. From this, it was clarified that the regioselectivity was 
reversed depending on the presence or absence of the ligand in the reaction using Ag2CO3 as 








Our Synthetic Plan  
As shown in Scheme 1, Uro-C is chemically synthesized but Uro-C 3-glur is not yet 
synthesized62,67. Since Uro-C has three hydroxyl groups at the reaction site, the Uro-C 
derivative can be obtained by intramolecular biaryl coupling reaction by using a protecting 
group different from the hydroxyl group at the 8-position and the 9-position. Then, we realized 
that Urolithin C 3-glucuronide could be synthesized by removing only one protecting group 




 Scheme 3. 
 
  
3.2.1 Synthesis of carboxylic acid derivative 
According to the retrosynthetic analysis we chose 3,4-dimethoxybenzaldehyde 2 as the first substrate. 
Starting material 2 was converted into iodine compound 3, with reference to a published paper 73, 
followed by demethylation using BBr3. As depicted in Scheme 4, the iodine compound 3 was 
transformed into its MOM ether 5.74 The substrate 5 was subjected to Pinnick oxidation to yield 








Scheme 4. Synthesis of carboxylic acid derivative 
 
 
3.2.2 Synthesis of monobenzyl derivative 
For Esterification, commercially available resorcinol 7 was monobenzylated with benzyl 





Scheme 5. Synthesis of monobenzyl derivative 
 
3.2.3 Intramolecular coupling reaction for 10a and 10b 
Treating carboxylic acid 6 with prepared monobenzyl derivative 8, using N,N’-
dicyclohexylcarbodiimide (DCC) gave the coupling precursor 9 through condensation.78-79 




biaryl coupling reaction afforded a mixture of compound 10a and its regioisomer 10b in the 




Scheme 6. Intramolecular coupling reaction for 10a and 10b 
 
 
Next, glucuronide which is a moiety of the urolithin C 3-glucuronide was constructed following 
a known procedure.83-84 The desired product 10a was isolated from the regioisomers (10a and 
10b), and these MOM groups were deprotected by concentrated hydrochloric acid (HCl) to 
give Uro-C derivative 11 without further purification. The resulting compound was reacted 
with acetic anhydride (Ac2O) to obtain the protected compound 12.
85-86 Hydrogenation of the 
compound 12 with 10% Pd/C under H2 yielded the hydroxyl compound 13 as a crude mixture.
31 
The glycosylation reaction of the compound 13 and the already prepared trichloroacetoimidate 
14 was performed based on the conditions described in scheme 7 to yield the precursor 15 of 
Uro-C 3-glur.64  Finally, the synthesis of Urolithin C 3-glucuronide (1) was achieved by 



























3.3 Experimental Section  
General: All reactions were executed under N2 atmosphere. Reaction solvents were used after 
purification by the standard methods. Reaction progress was observed with the help of thin-
layer chromatography by making use of silica gel (70 F254) TLC plates and UV light as an agent 
for visualizing. Silica gel (particle size: 100−200 and 230−400 mesh). Melting points (mp) 
were obtained using the Yanaco micro melting point apparatus and are uncorrected. With the 
Shimadzu FTIR 8400 spectrophotometer, the IR spectra were acquired. The JOEL α-400 MHz 
instrument was utilized for obtaining 1H and 13C NMR spectra with the couplings being shown 
in Hertz and chemical shift being expressed as 𝛿 ppm. Silica gel column chromatography was 








Under N2, 3,4-dihymethoxybenzaldehyde (2) (4.0 g, 24.0 mmol) was dissolved in  DCM (180 
mL) followed by the addition of AgTFA (6.38 g, 28.8 mmol) and slow addition of I2 (7.34 g, 
28.8 mmol) using a dropping funnel and kept at stirring at 55 ° C for 2 days. The reaction 
mixture was filtered, transferred into a separatory funnel, washed with sat. NaS2O3 aq. (200 
mL × 3), washed with Brine (200 mL), dried with MgSO4, concentrated, and the solvent was 
evaporated under reduced pressure to leave a brown solid residue. Obtain (10.0 g). The 
obtained solid residue was subjected to open column chromatography (φ = 4.8 cm, l = 7 cm, 
H: A = 5: 1) with Hexane: AcOEt = 6: 1 to 5: 1 to yield 3 (5.40 g, 77%) 
White solid: mp 138-140 °C (lit. mp 137-139 °C) 










Under a nitrogen atmosphere, 2-Iodo-4,5-dimethoxybenzaldehyde (3) (9.9 g, 34 mmol) was 
dissolved in  DCM (100 mL) and stir at -78 ° C for 10 minutes, BBr3 (17% in DCM, 81 mL, 
81 mmol) was added dropwise using a dropping funnel, and the mixture is returned to room 
temperature and stirred for 4 hours. The reaction was quenched with ice H2O (200 mL) 
followed by the addition of 1M HCl. The aqueous layer was extracted with EtOAC 3 times, 
one time with brine, dried over MgSO4, and concentrated under reduced pressure. Black 
residue 4 was obtained  (5.87 g, 66%).  
Black solid: mp 169-171 °C (lit. mp 169-171 °C) 























K2CO3 (122 mg, 0.88 mmol) was added to a solution of substrate 4 (31 mg, 0.11 mmol) in 
acetone (2 mL), which was stirred until the temperature reached 0 ℃ under an N2 atmosphere. 
MOMCl (0.045 mL, 0.51 mmol) was slowly poured into the mixture over a period of 15 mins, 
keeping the temperature at 0 ℃. After adding all the reagents, the temperature increased to 
room temperature. The reaction mixture was stirred for another 1 h at room temperature. The 
reaction mixture was then quenched with saturated aqueous NH4Cl at 0 ℃ and extracted with 
CHCl3 (3 × 10 mL). The combined extracts were washed with saturated aqueous NaHCO3 (2 
× 10 mL) and saturated brine (1 × 10 mL). The combined organic layer was dried over MgSO4, 
filtered, and concentrated under reduced pressure. The residue was purified using silica gel 
column chromatography (hexane/ethyl acetate = 6:1) to afford 5 (39.8 mg, 97%) as a yellow 
solid: mp 79.2-80.7 ℃; 1H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.68 (s, 1H), 7.66 (s, 1H), 
5.31 (s, 2H), 5.27 (s, 2H), 3.53 (s, 3H), 3.50 (s, 3H); 13C NMR (100MHz, CDCl3) δ 194.6, 
152.6, 147.4, 129.3, 126.1, 116.6, 95.1, 95.0, 93.2, 56.6, 56.4; IR (KBr) v 2955, 2360, 1682, 

















To a solution of the 5 (9.2 g, 26.1 mmol) in t-BuOH (350 mL) and MeCN (85 mL) were added 
NaH2PO4∙2H2O (32.7 g, 209 mmol) and 2-methyl-2-butene (64 mL, 601 mmol). The solution 
was cooled to 0 ℃ and NaClO2 (19 g, 209 mmol) dissolved in H2O (175 mL) was slowly 
added. After stirring for 30 min, AcOEt and H2O were added. The organic layer was separated, 
and the aqueous layer was extracted with AcOEt (3 × 200 mL). The combined organic layer 
was washed with saturated brine (1 × 100 mL) and dried over MgSO4. The combined organic 
layer was filtered and concentrated under reduced pressure. The crude residue was purified by 
recrystallization from AcOEt to afford 6 (9.0 g, 94%) as a white powder: mp 163.8-165.0 ℃; 
1H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 7.77 (s, 1H), 5.28 (s, 2H), 5.26 (s, 2H), 3.52 (s, 
6H); 13C NMR (100MHz, DMSO-d6) δ 166.8, 149.5, 146.2, 128.3, 126.1, 118.8, 94.8, 94.6, 
85.8, 56.6, 55.9; IR (KBr) v  2991, 2511, 1693, 1587, 1434, 1330, 1157, 1074, 716 cm-1; HRMS 
















Acetone (44 ml) was added to 7 (5.3 g, 48.1 mmol) and K2CO3 (3.33 g, 24.0 mmol), and the 
mixture was stirred under a nitrogen atmosphere. BnBr (2.85 mL, 24.0 mmol) was added 
dropwise to the reaction solution over 10 minutes, and the mixture is stirred at 80 ° C. After 12 
hours, K2CO3 is filtered and washed with AcOEt, washed with water (20 mL × 2), and Brine 
(20 mL), dried with MgSO4 and concentrated to obtain a brown oily residue (9.6 g). The 
obtained oily residue was subjected to open column chromatography (φ = 4.8 cm, l = 5 cm, 
Hexane: AcOEt = 9: 1 to 4: 1 to obtain 8 as a pale-yellow (2.89 g, 60%). 
(Lit. mp 52 ℃)31, 32 
1H NMR (400 MHz, CDCl3) δ : 7.45-7.30 (m, 5H), 7.14 (t, J = 8.0 Hz, 1H), 6.57 (dd, J = 8.0 
Hz, J = 2.0 Hz, 1H), 6.49 (t, J = 2.0 Hz, 1H), 6.44 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 5.04 (s, 





















6 (2.4 g, 6.5 mmol) and DCC (4.0 g, 19.5 mmol) were dissolved in DCM (25 mL). To the solution, 8 
(1.3 g, 6.8 mmol) dissolved in DCM (25 mL) and DMAP (0.79 g, 6.5 mmol) were added, then the 
mixture was stirred for 1 day at room temperature. After the reaction, the mixture was filtered, and the 
solvent was removed in vacuo. The crude residue was purified by silica gel column chromatography 
(hexane/ethyl acetate/ dichloromethane = 5:1:1) to afford 9 (2.9 g, 82%) as a yellow solid: mp 61.2-
62.2 ℃; 1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.79 (s, 1H), 7.45-7.30 (m, 6H), 6.90-6.85 (m, 
3H), 5.30 (s, 2H), 5.28 (s, 2H), 5.07 (s, 2H), 3.53 (s, 6H); 13C NMR (100MHz, CDCl3) δ 163.8, 159.7, 
151.6, 150.7, 146.7, 136.6, 129.8, 128.6, 128.4, 128.0, 127.5, 126.7, 119.6, 114.2, 112.6, 108.7, 95.4, 
95.1, 86.7, 70.2, 60.4, 56.6, 56.5; IR (KBr) v 1678, 1284, 976 cm-1; HRMS (EI) m/z [M+] calcd for 


















3-(benzyloxy)-8,9-dimethoxymethoxy-6H-enzo[b,d]pyrane-6-one (9a) and 1-(benzyloxy)-




Under an N2 atmosphere, 9 (1.4 g, 2.54 mmol), Ag2CO3 (1.4 g, 5.09 mmol), and Pd(OAc)2 
(57.0 mg, 0.25 mmol) were dissolved in DMA (32 mL), then the mixture was stirred at 190 ℃ 
for 30 min. After being stirred, the reaction mixture was cooled to room temperature and 
filtered. Water was added to the mixture, and the aqueous layer was extracted with AcOEt (3 × 
100 mL). The combined organic layer was washed with water (5 × 20 mL), saturated brine (1 
× 20 mL), and dried over MgSO4. The combined organic layer was filtered and concentrated 
under reduced pressure. The crude residue was purified by silica gel column chromatography 
(hexane/ethyl acetate = 4:1) to afford a mixture of 10a and 10b (0.88 g, 82%) in the ratio 4.2:1 
as a yellow solid. 
 
Major isomer (9a) 
White solid: mp 121.7-122.4 ℃; 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 
7.71 (s, 1H), 7.47-7.33 (m, 5H), 6.99-6.92 (m, 2H), 5.43 (s, 2H), 5.34 (s, 2H), 5.13 (s, 2H), 3.57 (s, 
3H), 3.54 (s, 3H); 13C NMR (100MHz, CDCl3) δ 161.1, 160.0, 153.6, 152.2, 147.0, 136.1, 131.2, 
128.7, 128.3, 127.5, 123.5, 116.1, 114.1, 112.9, 111.3, 106.8, 102.6, 95.4, 95.1, 70.4, 56.6, 56.5; IR 
(KBr) v 1707, 1618, 1501, 1448, 1367, 1331, 1269, 1007 cm-1; HRMS (EI) m/z [M+] calcd for 







Minor isomer (9b) 
White solid: mp 114.0-114.9 ℃; 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 8.09 (s, 1H), 7.55-7.33 
(m, 6H), 7.71 (s, 1H), 7.03 (d, J = 7.4 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 5.32 (s, 2H), 5.22 (s, 2H), 
4.84 (s, 2H), 3.51 (s, 3H), 3.36 (s, 3H); 13C NMR (100MHz, CDCl3) δ 160.9, 156.9, 152.4, 152.0, 
146.8, 135.8, 130.3, 129.1, 128.8, 128.7, 128.6, 115.9, 115.3, 113.3, 110.6, 108.4, 107.7, 95.1, 94.3, 
71.6, 56.6, 56.4 ; IR (KBr) v 1711, 1603, 1506, 1462, 1359, 1283, 1070, 993 cm-1; HRMS (EI) m/z 
[M+] calcd for C24H22O7 422.1365, found 422.1377. 
 




10a (210 mg, 0.50 mmol) was dissolved in MeOH (6.6 mL) and concentrated HCl (0.047 
mL) was added. The mixture was heated to 80 ℃, and stirred for 15 min. After reacting, the 
solvent was removed under reduced pressure, which gave a solid residue, and was dissolved 
in AcOEt. The organic layer was washed with saturated aqueous NaHCO3 (2 × 5 mL) and 
saturated Brine (1 × 5 mL). The organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure to afford the crude product 11 (164 mg, 99%) as a white 
solid and was used without further purification: mp 206.0-206.7 ℃; 1H NMR (400 MHz, 
Acetone-d6) δ 7.95 (d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.53 (s, 1H), 7.48 (d, J = 7.4 Hz, 2H), 
7.39-7.28 (m, 3H), 6.97 (dd, J = 8.8 Hz, J = 2.5 Hz, 1H), 6.92 (d, J = 2.4 Hz, 1H), 5.20 (s, 
2H); 13C NMR (100MHz, Acetone-d6) δ 161.0, 160.7, 153.7, 153.0, 146.8, 137.8, 130.6, 
129.5, 129.3, 129.0, 128.5, 124.5, 115.4, 114.8, 113.4, 112.4, 110.8, 107.8, 103.2, 70.9 ; IR 
(KBr) v 3448, 3354, 1695, 1620, 1578, 1452, 1269, 1170 cm-1; HRMS (EI) m/z [M+] calcd 











To a solution of 11 (200 mg, 0.60 mmol) in pyridine (0.8 mL), Ac2O (0.22 mL, 2.4 mmol) was 
added. The reaction mixture was stirred at room temperature for 20 min and water was 
subsequently poured into the reaction mixture. The aqueous phase was acidified to pH 2 and 
extracted with AcOEt (3 × 3 mL). The combined organic phase was washed with 0.1 M HCl 
(3 × 3 mL), saturated brine (1 × 3 mL), and dried over MgSO4. The combined organic phase 
was filtered and concentrated under reduced pressure. The crude residue was purified by 
recrystallization from AcOEt to afford 12 (190 mg, 76%) as a white solid: mp 182.3-183.0 °C; 
1H-NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.84-7.81 (m, 2H), 7.46-7.34 (m, 5H), 7.00-6.93 
(m, 2H), 5.14 (s, 2H), 2.37 (s, 3H), 2.35 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 167.9, 167.5, 
161.0, 160.1, 152.6, 148.1, 141.7, 135.9, 134.4, 128.7, 128.3, 127.6, 125.4, 124.0, 118.2, 116.2, 
113.3, 110.4,  102.7,  70.5,  20.8,  20.5;  IR  (KBr)  1736,  1620  cm-1;  HRMS  (EI) m/z [M+]  


















To a solution of 12 (174 mg, 0.41 mmol) in EtOH/AcOEt (3.6 mL/3.6 mL), 10% Pd-C (112 
mg) was added. Under an H2 atmosphere, the reaction mixture was stirred at room temperature 
for 30 min and hydrogenated. The mixture was filtered to remove the catalyst, then 
concentrated under reduced pressure to  afford  the  crude  product 13  (126  mg,  93%)  as  a  
white  solid  which  was  used  without  further purification: mp 180.9-182.7 °C; 1H-NMR 
(400 MHz, acetone-d6) δ 8.08 (dd, J = 12.4 Hz, J = 8.8 Hz, 3H), 6.92 (dd, J = 8.8 Hz, J = 2.4 
Hz, 1H), 6.82 (d, J = 2.8 Hz, 1H), 2.36 (s, 3H), 2.35 (s, 3H); 13C-NMR (100 MHz, acetone-
d6) δ 132.4, 130.1, 128.8, 68.2, 38.7, 30.9, 30.3, 29.7, 28.9, 23.7, 23.0, 14.0, 10.9; IR (KBr)  
3398,  1705,  1622,  1452,  1371.3,  1200,  923  cm-1;  HRMS  (EI) m/z [M+]  calcd  for  






















Under an N2 atmosphere, to a solution of 13 (115 mg, 0.35 mmol), MS3Å (150 mg) and 
trichloroacetoimidate 14 (290 mg, 0.59 mmol) in anhydrous DCM (7 mL) at 0 ℃, BF3∙OEt2 
(0.07 mmol) were added. After 2 h, the reaction mixture was quenched with NEt3 and 
concentrated in vacuo. The crude residue was purified by silica gel column chromatography 
(hexane/ethyl acetate = 3:1 to 1:1) to afford 15 (48.3 mg, 23%) as a white solid: mp 219.7-
220.6 ℃; 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 7.87-7.83 (m, 2H), 6.99 (dd, J = 7.8 Hz, 
J = 2.0 Hz, 2H), 5.39-5.24 (m, 4H), 4.24 (q, J = 3.2 Hz, 1H) 3.75 (s, 3H), 2.37 (s, 3H), 2.35 (s, 
3H), 2.08 (d, J = 8.4 Hz, 9H); 13C NMR (100MHz, CDCl3) δ 170.0, 169.3, 167.5, 166.6, 159.7, 
158.3, 152.2, 148.2, 142.2, 133.8, 125.6, 124.2, 118.6, 116.6, 114.5, 112.6, 105.1, 98.5, 72.7, 
71.6, 70.8, 68.9, 53.1, 20.8, 20.6, 20.5 ; IR (KBr) v 1757, 1620, 1572, 1493, 1251, 1173,1043 
cm-1; [α]25.1D −35.1 (c 0.5, CHCl3); HRMS (EI) m/z [M



















15 (20 mg, 0.03 mmol) was dissolved in MeOH/THF/H2O (0.25 mL/0.5 mL/0.25 mL) and KOH (13.5 
mg, 0.24 mmol) was added to the solution, then the reaction mixture was stirred at room temperature 
for 30 min. The mixture was quenched with Amberlite to pH 4, filtered and concentrated under 
reduced pressure. The crude residue was purified by silica gel column chromatography (MeOH/H2O = 
1:9 ) to afford Urolithin C 3-glucuronide (1) (11.6 mg, 82%) as a brown solid: mp 179.0-179.6 ℃; 
1H NMR (400 MHz, MeOH-d4) δ 7.89 (d, J = 8.8 Hz, 1H), 7.56 (s, 1H), 7.42 (s, 1H), 7.08-7.01 (m, 
2H), 5.09 (dd, J = 5.6 Hz, 2.0 Hz, 1H), 4.07 (d, J = 9.6 Hz, 1H), 3.66-3.51 (m, 3H); 13C NMR 
(100MHz, MeOH-d4) δ 161.9, 158.2, 153.6, 151.4, 146.6, 129.5, 123.2, 114.1, 113.6, 113.2, 111.9, 
106.6, 104.5, 100.8, 76.0, 73.2, 71.7, 29.4 ; IR (KBr) v 3321, 1718, 1620, 1506, 1267, 1038 cm-1; 





















Finding active compounds from existing chemicals is typically the first step in a drug research 
and development project. While several pharmaceutical companies have their libraries with 
millions of compounds, maintaining the library and performing high-throughput screening are 
both expensive. Virtual scanning is a new way to complete the screening of millions of millions 
of compounds within a few days38. When the 3D structure of the target protein is visible, 
molecular docking is one of the most commonly used virtual screening methods. This approach 
was able to predict the ligand-protein binding affinity as well as the structure of the protein-
ligand complex, which is useful knowledge for lead optimization. Indeed, molecular docking 
has been used for more than three decades, and it has resulted in the discovery and development 
of a large number of new drugs.39 Although it will undoubtedly continue to play an important 
role, molecular docking is still a long way from being a complete success in terms of success 
rate. This is also why high-throughput screening is still commonly used in many 
pharmaceutical firms today. The docking-based virtual screening will never have a chance to play 
an irreplaceable role in drug discovery and development until its success rate is essentially 
improved. 
 













4.1 Protein-ligand complex structure by docking 
The 3D structure of a protein-ligand complex provides atomic-level information on the ligand-
target protein binding process, which is especially useful for lead optimization. Several studies 
have shown that the docked binding conformation of a ligand can vary significantly from the 
experimentally determined structure,  especially, when the ligand is of high flexibility with a 
small energy barrier between different conformations.40 Present docking techniques, for 
example, have difficulty treating ligands with long-chain or carbohydrate moieties with 
precision. If the binding pocket contains residues with flexible chains or is formed by flexible 
loops, the situation becomes even more difficult. Not only could the binding pocket be shifting 
on its own all the time, but ligand binding could also cause drastic changes in the pocket profile. 
There is currently no docking software that can accurately deal with the entire intrinsic 
versatility of the protein structure as well as the mediated transformation of the protein structure. 






    
The molecular docking mechanism is depicted in this diagram. 
(A) The ligand's three-dimensional structure; (B) the receptor's 
three-dimensional structure; (C) The ligand is docked into the 
receptor's binding cavity and the putative conformations are 
explored; (D) The most probable binding conformation and the 
associated intermolecular interactions are established. In stick 
representation, the ligand (magenta carbon) and active site 
residues (blue carbon) are shown. Water is depicted as a white 
disk, with dotted lines indicating hydrogen bonds. 
 
 
Binding thermodynamics & kinetics 
If the drug has a higher binding affinity and a longer residence period in the binding pocket, it may 
have a better therapeutic effect. The Gibbs free energy (G), which is the amount of binding enthalpy 
(H) and entropy change (S), determines binding affinity. Both words are associated with atomic 
interactions, but striking a balance between them when optimizing drug candidates is difficult.41 
We are still in the early stages of thermodynamically guided drug design, even though several 
efforts have been devoted to thermodynamic optimization and several methods have been published, 
such as enthalpic optimization, thermodynamic optimization plots, and the enthalpic efficiency 
index. Furthermore, the drug's kinetic residence period is measured by drug-target interaction and 
dissociation rates. In high-throughput virtual screening, however, no docking software for kinetic 






In addition to the expected behavior, molecular docking has a flaw in terms of covalent binding. If 
a weak covalent bond forms between the ligand and protein residues, such as cysteine, the situation 
becomes more complicated, as the complex structure undergoes intrinsic vibration. As a result, 
thermodynamic and kinetic calculations of weak covalent bonding between protein and ligand are 
difficult. Furthermore, due to the difficulty of disassociation, if off-target binding occurs, covalent 
ligands are more likely to be associated with toxicity than noncovalent ligands. While the US FDA 
has approved several covalent medications, mainly for the treatment of infections, cancer, 
gastrointestinal disorders, central nervous system, and cardiovascular indications, there is still a 




Drug designers and chemical biologists are becoming increasingly interested in the binding of 
ligands to nucleic acids (RNA or DNA). It is, however, a new challenge for molecular modelers. 
Given the unique 3D structure of nucleic acids, docking must contend with both the ribose moiety's 
high structural versatility and extremely anisotropic charge distributions compared to proteins, 
resulting in additional variability in predicted binding poses and affinity.43 Because of the lack of 
suitable software and the 3D structure of nucleic acids, molecular docking may be of little use in 
the development of nucleic acid drugs.  
           Virtual screening through molecular docking, on the other hand, has already proven to be 
effective in a number of new drug development ventures and is now widely used in both academic 
institutions and the pharmaceutical industry. More and more structures will be possible as 
technology for evaluating the structures of biomacromolecules advances, and molecular docking 
will continue to play an important role in lead discovery and optimization. However, as previously 
said, this technology is still far from being a complete success. Future research should focus on 
accurately predicting binding thermodynamics and kinetics constants, as well as reproducing 
protein-ligand complex structure while accounting for overall protein versatility and solvent 
molecules, dealing with covalent binding as well as other biomacromolecule targets such as nucleic 
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Structure-Based Drug Design (SBDD) 
In pharmaceutical research and development, understanding the concepts by which small-
molecule ligands identify and interact with macromolecules is critical (R & D).44 SBDD is the 
systematic use of structural data (e.g., macromolecular targets, also known as receptors) 
obtained either experimentally or by computational homology modeling.45 The aim is to create 
ligands with unique electrostatic and stereochemical properties that will bind to receptors with 
high affinity. Since three-dimensional macromolecular structures are available, a thorough 
examination of the binding site topology, including the existence of clefts, cavities, and sub-
pockets, is possible. Charge distribution and other electrostatic properties may also be closely 
examined. Current SBDD methods allow the development of ligands with the properties 
required for effective modulation of the target receptor. High-affinity ligands selectively 
modulate a validated drug target, interfering with particular cellular processes and resulting in 
the desired pharmacological and therapeutic results.46 SBDD is a cyclic process that involves 
acquiring information in steps. In silico experiments are used to find possible ligands starting 
with a known target structure. Following these molecular simulation techniques, the most 
promising compounds are synthesized.47 Following that, various experimental platforms are 
used to assess biological properties such as potency, affinity, and efficacy. The three-
dimensional structure of the ligand-receptor complex can be solved once active compounds 
have been detected. The available structure allows for the observation of a number of 
intermolecular features that aid in the molecular recognition process. The study of binding 
conformations, characterization of key intermolecular interactions, characterization of 
unknown binding sites, mechanistic studies, and the elucidation of ligand-induced 
conformational changes all benefit from structural descriptions of ligand-receptor complexes. 
Biological activity data is combined with structural information once a ligand-receptor 
complex has been determined. 47,48. As a result, the SBDD process is restarted with new steps 
to add molecular modifications that may improve the affinity of new ligands for the binding 
site. Since significant conformational change can occur upon ligand binding, the target 
receptor's flexibility is an important factor to consider in the modeling process. Techniques like 









Protein-Protein Interaction Inhibitors and Molecular Docking 
Interactions between various classes of proteins regulate a lot of cellular and biochemical 
processes.54 Defective protein-protein interactions (PPIs) are linked to a variety of diseases, 
including cancer; as a result, this form of intermolecular occurrence is a highly appealing target 
in drug development.55 The use of biochemical and biophysical data to direct the docking 
process is a unique technique. PPI interfaces have been established and the reciprocal 




4.2 Results and Discussion 
Structurally similar eight molecules synthesis is reported in our earlier papers. In this thesis 
we have explored the docking studies of these molecules in two proteins i.e., CYP1B1 and 
BCL2.  
The docking results of the reported molecules with CYP1B1 protein are tabulated in table 1 
and the docking images can be seen in below. All the reported molecules show high binding in 
CYP1B1 protein and the binding energy ranges from 7.3 to 10.6 Kcal/mole. The high values 
of binding energy attribute to higher inhibition of the protein and thus all these molecules can 
act as a potent inhibitor of CYP1B1 protein. Amongst the reported molecules Urolithin M 7-
Glucuronide  shows highest binding of -10.6 Kcal/mol in the protein cavity. Ligand molecules 
are stabilized in the protein cavity by hydrophobic interactions and hydrogen bonds. The 
number of hydrogen bonds explains the stable binding between ligand and protein and during 
the transport process the ligand gets least released due to external pressure. On an average one 
hydrogen bond is formed by this series in the protein pocket and the hydrogen bond with 
glycine is most prominently visible.  CYP1B1 protein has a reported inhibitor and the energy 
of all the molecules is greater than the inhibitor reported. The docking images are shown in 
three different styles to better understanding the ligand protein binding. The first image shows 
only the ligand and the amino-acid involved in hydrogen bonding with it, second image shows 
cartoon view of protein showing the coiling of protein and the third image shows the protein 
in mesh form helping us understand the penetration of the ligand in the protein. On visualizing 
the protein in surface, the ligand was completely encapsulated in the cavity and hence mesh 
visualization is preferred. The entire series of molecules show similar behavior and hence all 




coiling is visible and how well the ligands occupy the cavity is seen. Thus, all the molecules 
reported in this paper show significant affinity towards CYP1B1 protein and they can 
prominently act on inhibition of its activity. 
4.3 Procedure 
Molecular docking experiments were performed using Autodock vina software. All the 
chemical structures were drawn in ChemDraw and their 3D structures were procured from 3D 
corona software. A protein PDB file was obtained from an online depository of RCSPBD. The 
protein was cleaned to remove water, heteroatoms, and ligand molecules. The cleaned protein 
was converted into pdbqt file using MGL Tools software. Docking experiments were 
performed by keeping protein rigid and allowing the ligand to occupy any place in the cavity. 





























4.4 Molecular Docking of synthesized compounds in CYP1B1.  
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1.  Hyalodendriol C 
 




2.  Graphislactone 
G 
 
-9.2  1 2.7 HIS-227 
3.  Graphislactone 
A 
 
-7.5  1 2.2 ASN-228 
4.  Graphislactone B 
 
-7.1  1 2.5 SER-239 
5.  Urolithin 3-C 
glucuronide 
 





6.  Urolithin M 7-
glucuronide 
 
-10.6  2 2.3,2.6 HIS-227,GLN-
332 
7.  Palmariol A 
 
-8.2  2 2.2,2.1 ARG-117,ILE-
399 
8.  Palmariol B 
 







4.6 Docking images of synthesized compounds in BCL2 pocket 
Docking results of a series of reported compounds in BCL2 protein are shown in Table 2 and 
the docking images are shown below. The series shows binding energy ranging from -4.8 to -
7.6 Kcal/mole. The negative sign of the binding energy attributes to the bound state and hence 
the values of binding energy are seen for commenting on results. Amongst the series PA shows 
highest binding energy -8.2 Kcal/mole. The reported inhibitor of BCl2 shows -4.8 Kcal/mole 
binding energy and one hydrogen bond with histidine molecule. The reported series of 
molecules shows binding with glycine molecule.  All the molecules show at least one hydrogen 
bond with amino acids in the cavity of the protein. UM shows highest number of hydrogen 
bonds i.e., 7 which means it is occupying the protein volume completely. PM with highest 
binding energy shows 4 hydrogen bonds showing hydrophobic interactions with the protein 
and sitting the pocket correctly. Docking images are shown in three ways, the first one shows 
ligand and amino acid residue involved in binding, second one shows protein in cartoon view 
and third one shows the ligand occupying the pocket in the protein. This series shows high 
occupancy in the cavity of the protein. The ligands penetrate the protein cavity and are 
stabilized by hydrogen bonds and hydrophobic interactions. BCl2 protein shows a well-defined 
pocket and the entire series occupies this pocket effectively. This can be seen from the docking 
images in surface view. Thus, the entire series of reported molecules can act as a good inhibitor 








































































































Urolithin C 3-Glucuronide 
 
 





















4.7 Table 2. Docking results of synthesized compounds in BCL2 








Amino acid residue 
involved in bonding 
1.  Hyalodendriol C -7.1 2 2.1,2.3 GLN80, MET82 
2.  Graphislactone G -6.6 1 2.1 GLN85 
3.  Graphislactone A -6.6 1 2.3 GLN87 
4.  Graphislactone B -6.5 1 2.3 GLN85 
5.  Urolithin 3-C 
glucuronide 
-4.8 1 2.6 ASP67 







7.  Palmariol A -8.2 4 2.1,2.5,2.1,2.6 ASN82, MET83, 
SER77 
8.  Palmariol B -5.3 2 2.8,2.3 ARG131 
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